Revision history of "Development of a monoclonal antibody with a more favourable safety profile for psoriasis treatment" (Q77974)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 October 2024

  • curprev 05:5105:51, 13 October 2024DG Regio talk contribs 89,311 bytes −5 Changed label, description and/or aliases in pt
  • curprev 05:5105:51, 13 October 2024DG Regio talk contribs 89,316 bytes +81 Set a claim value: summary (P836): O controlo do processo de produção de medicamentos biológicos e, em particular, de anticorpos monoclonais é muito complexo, o que, em combinação com o tamanho das partículas (aproximadamente 150 kDa), a pluralidade e diversidade das modificações pós-traducionais das proteínas, resulta no facto de não serem um produto completamente homogéneo. Na mesma embalagem de uma dada droga biológica, podemos ter um número de moléculas ligeiramente diferentes co...

20 March 2024

12 January 2024

11 June 2023

24 May 2023

2 March 2023

  • curprev 16:4516:45, 2 March 2023DG Regio talk contribs 86,480 bytes −867 Changed label, description and/or aliases in lv, ro, it, fr, da, el, fi, es, cs, et, ga, sk, lt, hu, sv, de, hr, pt, bg, nl, sl, mt, and other parts

25 October 2022

19 October 2022

17 October 2022

25 July 2022

  • curprev 19:5619:56, 25 July 2022DG Regio talk contribs 85,691 bytes +55,433 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et,

19 January 2022

15 January 2022

16 December 2021

7 December 2021

30 November 2021

  • curprev 14:3114:31, 30 November 2021DG Regio talk contribs 18,169 bytes +2,923 Created claim: summary (P836): Le contrôle de la production de médicaments biologiques, et en particulier d’anticorps monoclonaux, est très complexe, ce qui, en combinaison avec la taille des particules (environ 150 kDa), la multiplicité et la variété de la modification des protéines post-traductionnelles, ne constitue pas un produit totalement homogène. Dans le même emballage d’un médicament biologique donné, nous pouvons avoir un certain nombre de molécules légèrement diffé...
  • curprev 14:3114:31, 30 November 2021DG Regio talk contribs 15,246 bytes +178 Changed label, description and/or aliases in fr: translated_label

29 October 2020

14 October 2020

  • curprev 10:5110:51, 14 October 2020DG Regio talk contribs 15,508 bytes +157 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 10:5110:51, 14 October 2020DG Regio talk contribs 15,351 bytes −166 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 10:5110:51, 14 October 2020DG Regio talk contribs 15,517 bytes +2,732 Created claim: summary (P836): Control of the production process of biological drugs and in particular monoclonal antibodies is very complex, which, in combination with particle size (approximately 150 kDa), the plurality and diversity of posttranslational modifications of proteins, results in the fact that they are not a completely homogeneous product. In the same packaging of a given biological drug, we may have a number of molecules slightly different with non-critical qua...
  • curprev 10:5110:51, 14 October 2020DG Regio talk contribs 12,785 bytes −2,270 Removed claim: summary (P836): Control of the production of biological medicines, and in particular monoclonal antibodies, is very complex, which, combined with the particle size (about 150 kDa), the multiplicity and the diversity of protein modification, has the effect that they are not a completely homogeneous product.In the same packaging of a given biological medicine, we can have a number of molecules with slightly different qualitative parameters, i.e. those that do n...

25 September 2020

23 September 2020

15 July 2020

9 June 2020

6 June 2020

26 March 2020

4 March 2020

  • curprev 08:5508:55, 4 March 2020DG Regio talk contribs 13,342 bytes +2,270 Created claim: summary (P836): Control of the production of biological medicines, and in particular monoclonal antibodies, is very complex, which, combined with the particle size (about 150 kDa), the multiplicity and the diversity of protein modification, has the effect that they are not a completely homogeneous product.In the same packaging of a given biological medicine, we can have a number of molecules with slightly different qualitative parameters, i.e. those that do not...

18 February 2020

8 February 2020

31 January 2020

13 January 2020